The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Low-dose dexamethasone suppression testing has been recommended for biochemical screening when Cushing's syndrome is suspected. The criterion for normal suppression of cortisol after dexamethasone is controversial. To assess diagnostic utility (sensitivity), we report the results of low-dose dexamethasone suppression testing in 103 patients with spontaneous Cushing's syndrome. There were 80 patients with Cushing's disease (78%), 13 with the ectopic ACTH syndrome (13%), and 10 with cortisol-producing adrenocortical adenomas (10%). Fourteen (18%) of 80 patients with Cushing's disease suppressed serum cortisol to less than 5 micro g/dl (<135 nmol/liter) after the overnight 1-mg test, whereas six patients (8%) actually showed suppression of serum cortisol to less than 2 micro g/dl (<54 nmol/liter). In addition, the 2-d, low-dose dexamethasone suppression test yielded false-negative results in 38% of patients when urine cortisol was used and 28% when urinary 17-hydroxycorticosteroids were used. Serum cortisol after the 1-mg test correlated with baseline urinary free cortisol (r = 0.705, P < 0.001), plasma ACTH level (r = 0.322, P = 0.001), and urinary free cortisol after the 2-d test (r = 0.709, P = 0.001). This study provides evidence that low-dose dexamethasone may suppress either plasma cortisol or urinary steroids to levels previously thought to exclude Cushing's syndrome and that these tests should not be used as the sole criterion to exclude the diagnosis of endogenous hypercortisolism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because some patients with Cushing's disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion misclassified up to 15% of such patients as negative (81,82).”
From The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. (2008) · cites this paper as [81]
In the citing paper
“Therefore, they may fail to detect cyclical CS during a low-cortisol phase (“off-cycle”) (a form of CS marked by intermittent cortisol excess) and may also yield normal or borderline results in patients with mild CS who have lower or fluctuating cortisol secretion (73, 90-93).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [73]
Citations
Cites
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Self-citationTauchmanovà, L., Rossi, R., Biondi, B., Pulcrano, M., Nuzzo, V., Palmieri, E.-A., Fazio, S., & Lombardi, G. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011766 · Cited by 400
Cushing's syndrome: a review of diagnostic tests.
Crapo, L. (1979) · Metabolism · doi:10.1016/0026-0495(79)90097-0 · Cited by 393
Diagnosis and Management of Cushing’s Syndrome: Results of an Italian Multicentre Study 1
Invitti, C., Giraldi, F. P., De Martin, M., & Cavagnini, F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5465 · Cited by 336
Adrenal incidentaloma: a new cause of the metabolic syndrome?
Terzolo, M., Pia, A., Alì, A., Osella, G., Reimondo, G., Bovio, S., Daffara, F., Procopio, M., Paccotti, P., Borretta, G., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8277 · Cited by 322
The Cushing Syndrome: An Update on Diagnostic Tests
Kaye, T. B., & Crapo, L. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-434 · Cited by 310
Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome.
Papanicolaou, D. A., Mullen, N., Kyrou, I., & Nieman, L. K. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020534 · Cited by 241
A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome
Newell‐Price, J., Trainer, P., Perry, L., Wass, J., Grossman, A., & Besser, M. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02918.x · Cited by 229
Aron, D. C. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1780 · Cited by 226
Self-citation
Cited by
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
“misclassified up to 15% of such patients as negative (81, 82).”
BackgroundSelf-citationAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132
“The presence of atypical presentations in Cushing’s syndrome including those seen in PCOS and pseudo-Cushing’s should alert the endocrinologist to carefully evaluate any woman with PCOS who have developed some of the features seen in Cushing’s syndrome, other than menstrual dysfunction and hyperandrogenism (281, 282).”
BackgroundLacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,165
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
“26”
Self-citationSecondary arterial hypertension: when, who, and how to screen?
Rimoldi, S. F., Scherrer, U., & Messerli, F. H. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht534 · Cited by 393
“8 mg/dL).(76) Hyper-/hypothyroidism Both hyper- and hypothyroidism have been associated with arterial hypertension.”
BackgroundCushing's syndrome: update on signs, symptoms and biochemical screening
Nieman, L. K. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0464 · Cited by 343
Cushing’s Syndrome: important issues in diagnosis and management
Findling, J. W., & Raff, H. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0997 · Cited by 294
Self-citationDiagnosis of Spontaneous Canine Hyperadrenocorticism: 2012 ACVIM Consensus Statement (Small Animal)
Behrend, E. N., Kooistra, H. S., Nelson, R., Reusch, C. E., & Scott-Moncrieff, J. C. (2013) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.12192 · Cited by 251
Approach to the Patient with Possible Cushing’s Syndrome
Boscaro, M., & Arnaldi, G. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0612 · Cited by 251
“Conversely, there is no cutoff that identifies all patients with Cushing’s syndrome considering that 8% of cases showed a suppression less than 2 g/dl despite the presence of disease (31).”
BackgroundCushing's syndrome: epidemiology and developments in disease management
Feelders, R., Sharma, S., & Nieman, L. (2015) · Clinical Epidemiology · doi:10.2147/clep.s44336 · Cited by 210
“8 μg/dL (50 nmol/L) on DST.(1,66) Multiple repeated tests may be needed to establish the diagnosis in these cases.”
InfluentialEsposito, F., Dusick, J. R., Cohan, P., Moftakhar, P., McArthur, D., Wang, C., Swerdloff, R. S., & Kelly, D. F. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1204 · Cited by 192
Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans.
Liu, H., Bravata, D. M., Cabaccan, J., Raff, H., & Ryzen, E. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02395.x · Cited by 178
Self-citationSalivary steroid assays – research or routine?
Wood, P. (2009) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2008.008208 · Cited by 174
Viardot, A., Huber, P., Puder, J. J., Zulewski, H., Keller, U., & Müller, B. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2264 · Cited by 172
Evaluation and treatment of Cushing’s syndrome
Nieman, L. K., & Ilias, I. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.01.059 · Cited by 169
Chronopharmacology of glucocorticoids
Scherholz, M. L., Schlesinger, N., & Androulakis, I. P. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.004 · Cited by 144
“Dexamethasone is also commonly used to suppress the HPA axis to mimic disease states for analysis of other synthetic glucocorticoids [90, 98, 99].”
BackgroundRaff, H., Sharma, S. T., & Nieman, L. K. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130035 · Cited by 141
“One study suggested that patients taking multiple medications are more likely to have a clinically inappropriate response to the oDST (263).”
InfluentialSelf-citationCushing’s syndrome: from physiological principles to diagnosis and clinical care
Raff, H., & Carroll, T. (2015) · The Journal of Physiology · doi:10.1113/jphysiol.2014.282871 · Cited by 137
“If there is not a significant gradient, then the excess ACTH is coming from a non-pituitary (ectopic) source, assuming the IPS catheters were placed correctly and there is not anomalous venous drainage from the pituitary (Doppman et al. 1999; Findling et al. 2004a).”
BackgroundInfluentialSelf-citationKidambi, S., Raff, H., & Findling, J. W. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0424 · Cited by 129
“In addition, the overnight 1 mg dexamethasone suppression test (DST) has been used as as creening test; however, it may lack adequate sensitivity and specificity to be a stand-alone test and needs to be complemented ( 9 ).”
MethodSelf-citationScreening and diagnosis of Cushing’s syndrome
Findling, J. W., & Raff, H. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.02.001 · Cited by 127
“It is predicted that this more stringent criterion will yield a diagnostic sensitivity of 95% to 98% [62], but that specificity (ie, false-positives) will suffer as a result.”
Self-citationShibli-Rahhal, A. A., Beek, M. J. V., & Schlechte, J. (2006) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2006.04.012 · Cited by 146
Pecori Giraldi, F., Ambrogio, A. G., De Martin, M., Fatti, L. M., Scacchi, M., & Cavagnini, F. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0596 · Cited by 121
“82% [16]”
Storr, H. L., Alexandraki, K. I., Martin, L., Isidori, A. M., Kaltsas, G. A., Monson, J. P., Besser, G. M., Matson, M., Evanson, J., Afshar, F., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1120 · Cited by 110
Vezzosi, D., Cartier, D., Régnier, C., Otal, P., Bennet, A., Parmentier, F., Plantavid, M., Lacroix, A., Lefebvre, H., & Caron, P. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02324 · Cited by 104
The diagnosis of Cushing’s syndrome
Carroll, T. B., & Findling, J. W. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9143-3 · Cited by 107
“However, this cutoff lacks sensitivity and results in a 15% false negative rate [32, 33].”
BackgroundSelf-citationDiagnosis of Cushing’s Syndrome in the Modern Era
Nieman, L. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.001 · Cited by 93
Methlie, P., Hustad, S., Kellman, R., Almås, B., Erichsen, M. M., Husebye, E. S., & Løvås, K. (2013) · Endocrine Connections · doi:10.1530/ec-13-0023 · Cited by 92
Tirabassi, G., Faloia, E., Papa, R., Furlani, G., Boscaro, M., & Arnaldi, G. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1146 · Cited by 90
Recent Updates on the Diagnosis and Management of Cushing's Syndrome
Nieman, L. K. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.2.139 · Cited by 85
“Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients
Mitchell, I. C., Auchus, R. J., Juneja, K., Chang, A. Y., Holt, S. A., Snyder, W. H., & Nwariaku, F. E. (2007) · Surgery · doi:10.1016/j.surg.2007.10.001 · Cited by 84
Pitfalls in the diagnosis and management of Cushing's syndrome
Bansal, V., Asmar, N. E., Selman, W. R., & Arafah, B. M. (2015) · Neurosurgical Focus · doi:10.3171/2014.11.focus14704 · Cited by 81
Adrenal incidentaloma: a diagnostic challenge
Anagnostis, P. G., Karagiannis, A. I., Τζιόμαλος, Κ., Kakafika, A. I., Athyros, V. G., & Mikhailidis, D. P. (2009) · HORMONES · doi:10.14310/horm.2002.1233 · Cited by 96
“or urine free cortisol and/or 17-hydroxycorticosteroids (17OH-corticosteroids) at 48h.(50) Serum cortisol”
BackgroundCushing's syndrome in pregnancy: an overview
Vilar, L., Freitas, M. D. C., Lima, L. H. C., Lyra, R., & Kater, C. E. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800015 · Cited by 77
Reimondo, G., Allasino, B., Bovio, S., Paccotti, P., Angeli, A., & Terzolo, M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02042 · Cited by 68
Nieman, L. K., Castinetti, F., Newell-Price, J. D. C., Valassi, E., Drouin, J., Takahashi, Y., & Lacroix, A. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00588-w · Cited by 88
Pitfalls in the diagnosis of Cushing's syndrome
Vilar, L., Freitas, M. D. C., Faria, M., Montenegro, R., Casulari, L. A., Naves, L., & Bruno, O. D. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800006 · Cited by 63
Erickson, D., Natt, N., Nippoldt, T., Young, W. F., Carpenter, P. C., Petterson, T., & Christianson, T. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2662 · Cited by 60
Diagnostic tests for Cushing’s syndrome differ from published guidelines: data from ERCUSYN
Valassi, E., Franz, H., Brue, T., Feelders, R. A., Netea-Maier, R., Tsagarakis, S., Webb, S. M., Yaneva, M., Reincke, M., Droste, M., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0967 · Cited by 58
Fagour, C., Bardet, S., Rohmer, V., Arimone, Y., Lecomte, P., Valli, N., & Tabarin, A. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0299 · Cited by 59
Briassoulis, G., Damjanovic, S., Xekouki, P., Lefebvre, H., & Stratakis, C. A. (2011) · Endocrine Practice · doi:10.4158/ep11061.ra · Cited by 48
“Despite the rarity of mutations, GR insensitivity is so widespread in ACTH-producing tumors that we take advantage of this phenomenon in diagnostic testing for CS by using various dexamethasone doses (and administration regimens) to distinguish among normal HPA axis function, pituitary and ACTH-dependent causes (Cushi…”
BackgroundAdrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment.
Mazzuco, T. L., Bourdeau, I., & Lacroix, A. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832b7043 · Cited by 48
Tritos, N. A., & Biller, B. M. K. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00015-0 · Cited by 51
Findling, J. W., & Raff, H. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.015 · Cited by 44
Self-citationCushing’s syndrome: comparison between Cushing’s disease and adrenal Cushing’s
Hirsch, D., Shimon, I., Manisterski, Y., Aviran-Barak, N., Amitai, O., Nadler, V., Alboim, S., Kopel, V., & Tsvetov, G. (2018) · Endocrine · doi:10.1007/s12020-018-1709-y · Cited by 48
Şahin, M., Kebapçılar, L., Taşlıpınar, A., Azal, Ö., Özgürtaş, T., Çorakçı, A., Akgül, E. Ö., Taşlıpınar, M. Y., Yazıcı, M., & Kutlu, M. (2009) · Internal Medicine · doi:10.2169/internalmedicine.48.1234 · Cited by 39
Martin, M. D., Giraldi, F. P., & Cavagnini, F. (2006) · Pituitary · doi:10.1007/s11102-006-0407-6 · Cited by 39
“8 μg/dl (50 nmol/l) or 5 μg/dl (140 nmol/l) [16, 17].”
Laboratory differentiation of Cushing's syndrome
Reimondo, G., Pia, A. R., Bovio, S., Allasino, B., Daffara, F., Paccotti, P., Borretta, G., Angeli, A., & Terzolo, M. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.10.036 · Cited by 43
Raff, H. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.005 · Cited by 34
Self-citationQueckenberg, C., Wachall, B., Erlinghagen, V., Gion, P. D., Tomalik‐Scharte, D., Tawab, M. A., Gerbeth, K., & Fuhr, U. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.006 · Cited by 34
Screening and diagnosis of Cushing's syndrome
Castro, M. D., & Moreira, A. C. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800004 · Cited by 34
Molecular Derangements and the Diagnosis of ACTH-Dependent Cushing’s Syndrome
Nieman, L. K. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab046 · Cited by 33
Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing’s syndrome?
Krarup, T., Krarup, T., & Hagen, C. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2262 · Cited by 30
Pathophysiology, Evaluation, and Medical Management of Adrenal Disorders
Kutikov, A., Crispen, P. L., & Uzzo, R. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00057-8 · Cited by 34
Case 36-2006: A 35-Year-Old Pregnant Woman with New Hypertension
Klibanski, A., Stephen, A. E., Greene, M. F., Blake, M. A., & Wu, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmcpc069027 · Cited by 34
The diagnosis and differential diagnosis of endogenous Cushing?s syndrome
Makras, P., Toloumis, G., Papadogias, D., Kaltsas, G., & Besser, M. (2006) · HORMONES · doi:10.14310/horm.2002.11189 · Cited by 35
Cushing's Syndrome: Where and How to Find It
Debono, M., & Newell-Price, J. D. C. (2016) · Frontiers of hormone research · doi:10.1159/000443861 · Cited by 38
Current Challenges and Future Directions in the Assessment of Glucocorticoid Status
Clarke, S. A., Eng, P. C., Comninos, A. N., Lazarus, K., Choudhury, S., Tsang, C., Meeran, K. M., Tan, T., Dhillo, W. S., & Abbara, A. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae016 · Cited by 38
Hwang, Y., Chung, J. H., Min, Y., Lee, M., Lee, M., & Kim, K. (2009) · Journal of Korean Medical Science · doi:10.3346/jkms.2009.24.1.46 · Cited by 32
Deutschbein, T., Unger, N., Hinrichs, J., Walz, M. K., Mann, K., & Petersenn, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0517 · Cited by 28
An Individualized Approach to the Evaluation of Cushing Syndrome
Sharma, S. T. (2017) · Endocrine Practice · doi:10.4158/ep161721.ra · Cited by 31
Diagnostic approach to Cushing disease
Gross, B. A., Mindea, S. A., Pick, A. J., Chandler, J. P., & Batjer, H. H. (2007) · Neurosurgical FOCUS · doi:10.3171/foc-07/09/e1 · Cited by 31
Chiodini, I., Ramos-Rivera, A., Marcus, A. O., & Yau, H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2018-00382 · Cited by 25
“Whereas some clinicians have cited a historic cutoff of #5 mg/dL (138 nM) as “normal,” the use of this historic cutoff misclassified up to 15% of patients with false-negative results [6, 28].”
BackgroundKaram, J. G., & McFarlane, S. I. (2007) · Therapy · doi:10.2217/14750708.4.5.641 · Cited by 30
Batista, D. L., Courcoutsakis, N. A., Riar, J., Keil, M. F., & Stratakis, C. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0985 · Cited by 25
Newell-Price, J. D. C. (2008) · Clinical Medicine · doi:10.7861/clinmedicine.8-2-204 · Cited by 32
Rasul, F. T., Jaunmuktane, Z., Khan, A. A., Phadke, R., & Powell, M. P. (2013) · Acta Neurochirurgica · doi:10.1007/s00701-013-1890-y · Cited by 23
Dynamic testing in Cushing’s syndrome
Kola, B., & Grossman, A. B. (2007) · Pituitary · doi:10.1007/s11102-007-0079-x · Cited by 26
“Lately, the effectiveness of the HDDST has been questioned as on several occasions the sensitivity and the specificity of the test appear to be less accurate than the pre-test statistical likelihood of CD [44].”
BackgroundOki, Y., Hashimoto, K., Hirata, Y., Iwasaki, Y., Nigawara, T., Doi, M., Sakihara, S., Kageyama, K., & Suda, T. (2009) · Endocrine Journal · doi:10.1507/endocrj.k09e-194 · Cited by 28
Golden, S. H., Malhotra, S., Wand, G. S., Brancati, F. L., Ford, D. E., & Horton, K. M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2674 · Cited by 27
Machado, M. C., Fragoso, M. C. B. V., Moreira, A. C., Boguszewski, C. L., Vieira Neto, L., Naves, L. A., Vilar, L., Araújo, L. A. D., Czepielewski, M. A., Gadelha, M. R., et al. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000174 · Cited by 21
“Finally, recent studies have verified the prolactin values in BIPSS that can be used to correct for possible false negative gradients (51,123,159,160).”
BackgroundNew Aspects in the Diagnosis and Treatment of Cushing Disease
Labeur, M. S., Theodoropoulou, M., Sievers, C., Páez-Pereda, M., Castillo, V. A., ARZT, E. S., & Stalla, G. K. (2006) · KARGER eBooks · doi:10.1159/000094325 · Cited by 25
Late-night salivary cortisol in normal subjects and in patients with Cushing’s syndrome
Jeyaraman, K., Ammini, A. C., Nandita, G., & Dwivedi, S. N. (2010) · Postgraduate Medical Journal · doi:10.1136/pgmj.2009.090787 · Cited by 21
“68 nmol/l was taken as a normally suppressible hypothalamicepituitarye adrenal axis.(18) Those who did not suppress cortisol to <49.”
MethodCushing’s syndrome: Why is diagnosis so difficult?
Aron, D. C. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9127-3 · Cited by 26
Self-citationÅsvold, B. O., Grill, V., Thorstensen, K., & Bjørgaas, M. R. (2012) · Endocrine Connections · doi:10.1530/ec-12-0047 · Cited by 20
Diagnóstico y diagnóstico diferencial del síndrome de Cushing
Santos, S., Santos, E., Gaztambide, S., & Salvador, J. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)70555-8 · Cited by 30
Reduced Insulin Sensitivity as a Marker for Acute Mountain Sickness?
Spliethoff, K., Meier, D., Herter‐Aeberli, I., Gassmann, M., Langhans, W., Maggiorini, M., Lutz, T. A., & Goetze, O. (2013) · High Altitude Medicine & Biology · doi:10.1089/ham.2012.1128 · Cited by 18
“The suppressive effect of dexamethasone on endogenous cortisol production was as expected (Findling et al, 2004; Miller et al, 1992): the dexa-methasone-treated group showed a marked decrease in the plasma levels of endogenous cortisol at HA4.”
Lindholm, J. (2013) · Pituitary · doi:10.1007/s11102-013-0509-x · Cited by 18
“[41] concluded that ‘‘patients with mild degrees of hypercortisolism are more likely to suppress their plasma cortisol to low levels after overnight 1-mg dexamethasone suppressions test’’.”
BackgroundOki, K., Yamane, K., Oda, Y., Kamei, N., Watanabe, H., Tominaga, A., Amatya, V. J., Oki, Y., & Kohno, N. (2008) · Journal of neurosurgery · doi:10.3171/2008.8.jns08154 · Cited by 17
Evaluation of endocrine tests. B: screening for hypercortisolism.
Holleman, F., Endert, E., Prummel, M. F., van Vessem-Timmermans, M., Wiersinga, W. M., & Fliers, E. (2005) · PubMed · Cited by 17
Roper, S. M. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa193 · Cited by 16
Role of salivary cortisol determinations in the diagnosis of Cushing syndrome
Raff, H. (2004) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000132655.69704.8c · Cited by 15
Self-citationDifficulty in the diagnosis of Cushing disease
Nieman, L. K. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0074 · Cited by 16
Budget impact of using midnight salivary cortisol in the diagnosis of hypercortisolism
León-Justel, A., Mangas, M. A., Fontán, R. I., Luque, J. C., Moreno, E. V., Atutxa, A. M., del Rey, T. H., Martin-Rodriguez, J. F., Soto-Moreno, A., & Leal-Cerro, A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.08.013 · Cited by 14
Steffensen, C., Thomsen, H. H., Dekkers, O. M., Christiansen, J. S., Rungby, J., & Jørgensen, J. O. L. (2016) · Clinical Endocrinology · doi:10.1111/cen.13071 · Cited by 14
Huayllas, M. K. P., Smith, L. M., Gallagher, J. C., Netzel, B. C., Singh, R. J., & Kater, C. E. (2021) · Clinical Endocrinology · doi:10.1111/cen.14445 · Cited by 14
Neurologic complications of disorders of the adrenal glands
Bertorini, T. E., & Pérez, Á. D. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4087-0.00050-4 · Cited by 16
“A cortisol level over 3 mg/dL suggests hypercortisolism (David, 1995; Findling et al., 2004).”
BackgroundHuayllas, M. K. P., Sirineni, G. K. R., Smith, L. M., Gallagher, J. C., Singh, R., Netzel, B. C., & Kater, C. E. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.19.21753 · Cited by 16
The 4‐mg intravenous dexamethasone suppression test in the diagnosis of Cushing’s syndrome
Jung, C., ALFORD, F. P., Topliss, D. J., Burgess, J. R., Long, F., Gome, J. J., Stockigt, J., & Inder, W. J. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03756.x · Cited by 15
Turan, H., Çatlı, G., Kardelen, A. D., Böber, E., Akıncı, A., Çetinkaya, S. Ç., Demirbaş, Ö., Er, E., Evliyaoğlu, S. O., Dündar, B. N., et al. (2022) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2021.2021.0152 · Cited by 13
“8 μg/dL is considered to be abnormal, with a sensitivity higher than 95% and a specificity of 80% (9).”
BackgroundDepartment of Medicine, Q. E. H., Ng, C., Lam, T., Au Yeung, Y., Choi, C., Iu, Y., Shek, C., & Tiu, S. (2017) · Hong Kong Medical Journal · doi:10.12809/hkmj176240 · Cited by 11
Estrategias para el despistaje de la HTA secundaria
Galvañ, V. G., & Giner, M. J. E. (2006) · Hipertensión · doi:10.1016/s0212-8241(06)71766-2 · Cited by 12
Romanholi, D. J. P. C., & Salgado, L. R. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800016 · Cited by 10
The Diagnosis of Cushing’s Syndrome
Nieman, L. K. (2011) · Endocrine updates · doi:10.1007/978-1-4614-0011-0_4 · Cited by 9
Blevins, L. S. (2013) · Wiley eBooks · doi:10.1002/9781118559406.ch8 · Cited by 9
Clinical Characteristics of Endogenous Cushing’s Syndrome at a Medical Center in Southern Taiwan
Tung, S., Wang, P., Liu, R., Chen, J., Hsieh, C., Kuo, M., Yang, J. W., Lee, W.-C., Cheng, M., & Lee, T. (2013) · International Journal of Endocrinology · doi:10.1155/2013/685375 · Cited by 8
“[1] showed that 18% of patients with CD had plasma cortisol levels suppressed to less than 5 μg/dL (false negative) after overnight LDDST, whereas 8% actually showed suppression of plasma cortisol to less than 2μg/dL.”
InfluentialKline, G. A., & Chin, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803412-5.00005-7 · Cited by 10
Reimondo, G., Allasino, B., Coletta, M., Pia, A. R., Peraga, G., Zaggia, B., Massaglia, C., Paccotti, P., & Terzolo, M. (2015) · International Journal of Endocrinology · doi:10.1155/2015/674734 · Cited by 8
“This particular endocrine disorder, which has been called subclinical Cushing’s syndrome (SCS) [9] or subclinical autonomous glucocorticoid hypersecretion [2], is difficult to characterize because of a spectrum of variation from normality to autonomy of cortisol secretion and since the degree of cortisol excess is oft…”
BackgroundPatients with the metabolic syndrome and a disturbed cortisol balance display more microalbuminuria
Janssen, S. F., Twickler, M., Jublanc, C., Cramer, M. J., & Bruckert, É. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.010 · Cited by 8
“Levels of serum cortisol that reached 50 nmol/L or more after LDDST were considered to be indicative of disturbed cortisol balance and these patients were described as having abnormal cortisol metabolism.(9,10) All patients with disturbed cortisol balance and those patients with normal suppression of cortisol after LD…”
Difficulties in Excluding Cushing Syndrome in Obese Subjects
Tran, H. A., & Petrovksy, N. (2006) · The Endocrinologist · doi:10.1097/01.ten.0000191747.48192.fb · Cited by 8
Metadata
- Authors
- Findling, J. W., Raff, H., & Aron, D. C.
- Affiliations
- Medical College of Wisconsin (US)
- Louis Stokes Cleveland VA Medical Center (US)
- Corresponding author
- Findling, James W.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-03
- Volume
- 89
- Issue
- 3
- Pages
- 1222-1226
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2165331817
- Semantic Scholar
- cffdec9ae0a9b75b511f9282c64f18235ed6715a
- Cited by
- 165
- References
- 26
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 8 · 2020: 2 · 2019: 5 · 2018: 7 · 2017: 9 · 2016: 6 · 2015: 8 · 2014: 7 · 2013: 12 · 2012: 5
- FWCI
- 8.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- low-dose dexamethasone suppression test, Cushing's syndrome, Cushing's disease, ectopic ACTH syndrome, endogenous hypercortisolism, diagnostic sensitivity, false-negative results, urinary free cortisol, urinary 17-hydroxycorticosteroids, ACTH
- MeSH terms
- Adult, Aged, Cushing Syndrome, Dexamethasone, Glucocorticoids, Humans, Hydrocortisone, Mass Screening, Sensitivity and Specificity, 17-Hydroxycorticosteroids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.